In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

The American College of Physicians issues new guidance on the prevention of episodic migraine with pharmacologic treatment recommendations.